| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Fmoc-N,N-dimethyl-L-Glutamine targets chemical reaction pathways in peptide synthesis rather than biological targets. As an N-protected amino acid derivative, the Fmoc group provides stability during solid-phase peptide synthesis. The compound is used as a building block for the synthesis of peptides containing N,N-dimethylglutamine residues. Its targets are chemical rather than biological, as it is primarily used as a research reagent for peptide synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies of Fmoc-N,N-dimethyl-L-Glutamine have focused on its role as a building block in solid-phase peptide synthesis. The compound's reactivity and stability have been characterized in various peptide synthesis applications. Its purity (≥98%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. These in vitro studies provide foundational data for understanding the compound's utility in peptide chemistry. |
| ln Vivo |
In vivo studies of Fmoc-N,N-dimethyl-L-Glutamine are not applicable as the compound is primarily used as a chemical reagent for peptide synthesis rather than as a therapeutic agent. The compound is not intended for administration to living organisms. Its applications are limited to chemical research and peptide synthesis. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| Enzyme Assay |
In vitro chemical assays for Fmoc-N,N-dimethyl-L-Glutamine involve testing its purity and reactivity as a peptide synthesis reagent. The compound's purity (≥98%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. Its reactivity in peptide coupling reactions is evaluated using standard peptide synthesis techniques. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays are not applicable for Fmoc-N,N-dimethyl-L-Glutamine as the compound is a chemical reagent used for peptide synthesis rather than a biological agent. The compound is not intended for cell-based studies as a direct pharmacological agent. Its applications are limited to chemical research and peptide synthesis. Cell-based assays may be used to evaluate the biological activity of peptides synthesized using this building block.
|
| Animal Protocol |
In vivo animal experiments are not applicable for Fmoc-N,N-dimethyl-L-Glutamine as the compound is a chemical reagent used for research rather than a therapeutic agent. The compound is not administered to animals for pharmacological evaluation. Its applications are limited to chemical research and peptide synthesis. The compound is not intended for in vivo use.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Fmoc-N,N-dimethyl-L-Glutamine are not applicable as the compound is a chemical reagent used for peptide synthesis rather than a therapeutic agent. It has a molecular weight of 396.44 and the molecular formula C22H24N2O5. The compound has a purity of ≥98% and is stored at 4°C. Its physicochemical properties are characterized for its use as a peptide synthesis reagent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Fmoc-N,N-dimethyl-L-Glutamine has been evaluated in the context of its use as a research chemical. As an amino acid derivative, it is expected to have low toxicity. The compound has a purity of ≥98%. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
Fmoc-N,N-dimethyl-L-Glutamine (CAS# 1146118-59-3) is also known as N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N5,N5-dimethyl-L-glutamine and Fmoc-Gln(Me2)-OH. It has the molecular formula C22H24N2O5 and a molecular weight of 396.44. The compound is an N-protected, N,N-dimethylated glutamine derivative used in solid-phase peptide synthesis. The Fmoc protecting group enables selective deprotection under mild conditions. It has a purity of ≥98%.
|
| Molecular Formula |
C22H24N2O5
|
|---|---|
| Molecular Weight |
396.436366081238
|
| Exact Mass |
396.168
|
| CAS # |
1146118-59-3
|
| PubChem CID |
89668277
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN(C)C(=O)CC[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
RSMCAOKIIZQPSD-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C22H24N2O5/c1-24(2)20(25)12-11-19(21(26)27)23-22(28)29-13-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,18-19H,11-13H2,1-2H3,(H,23,28)(H,26,27)/t19-/m0/s1
|
| Chemical Name |
(2S)-5-(dimethylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (252.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5224 mL | 12.6122 mL | 25.2245 mL | |
| 5 mM | 0.5045 mL | 2.5224 mL | 5.0449 mL | |
| 10 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
